Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Zhang, Hongtuan ^a   Qi, Can ^a   Wang, Andi ^a   Yao, Bing ^a   Li, Liang ^a   Wang, Yuzhuo ^b   Xu, Yong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOBINDIN 2; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SEMINAL VESICLE; TUMOR INVASION;

CALCIUM-BINDING PROTEINS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886306103     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-77     Document Type: Article

References (33)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 1 11 30 10.3322/caac.21166 23335087
2. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 10.3322/caac.20107 21296855
3. Screening and prostate-cancer mortality in a randomized European study. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, De Koning HJ, Auvinen A, N Engl J Med 2009 360 13 1320 1328 10.1056/NEJMoa0810084 19297566
4. PSA and other tissue kallikreins for prostate cancer detection. Stephan C, Jung K, Lein M, Diamandis EP, Eur J Cancer 2007 43 13 1918 1926 10.1016/j.ejca.2007.06.006 17689069 (Pubitemid 47287733)
5. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger MA, Blumenstein BA, Crawford ED, N Engl J Med 1998 339 15 1036 1042 10.1056/NEJM199810083391504 9761805 (Pubitemid 28457865)
6. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, Wyler S, J Transl Med 2011 9 162 10.1186/1479-5876-9-162 21943235
7. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M, J Transl Med 2012 10 156 10.1186/1479-5876-10-156 22862954
8. Targeting the endothelin axis in prostate carcinoma. Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E, Tumor Biol 2012 33 2 421 426 10.1007/s13277-011-0299-6
9. Developing a nanoparticle test for prostate cancer scoring. Huo Q, Litherland SA, Sullivan S, Hallquist H, Decker DA, Rivera-Ramirez I, J Transl Med 2012 10 44 10.1186/1479-5876-10-44 22404986
10. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. Garcia-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M, J Mol Endocrinol 2010 45 5 281 290 10.1677/JME-10-0059 20682642
11. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Miura K, Titani K, Kurosawa Y, Kanai Y, Biochem Biophys Res Commun 1992 187 1 375 380 10.1016/S0006-291X(05)81503-7 1520323
12. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein: molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Barnikol-Watanabe S, Gross NA, Götz H, Henkel T, Karabinos A, Kratzin H, Barnikol HU, Hilschmann N, Biol Chem Hoppe Seyler 1994 375 8 497 512 10.1515/bchm3.1994.375.8.497 7811391 (Pubitemid 2133728)
13. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M, Nature 2006 443 7112 709 712 10.1038/nature05162 17036007 (Pubitemid 44564715)
14. The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, Ogura A, Yoshikawa K, J Biol Chem 2000 275 41 31674 31681 10915798
15. Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. Islam A, Adamik B, Hawari FI, Ma G, Rouhani FN, Zhang J, Levine SJ, J Biol Chem 2006 281 10 6860 6873 10.1074/jbc.M509397200 16407280 (Pubitemid 43847622)
16. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M, J Mol Endocrinol 2010 45 5 281 290 10.1677/JME-10-0059 20682642
17. Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer. Kalnina Z, Silina K, Bruvere R, Gabruseva N, Stengrevics A, Barnikol-Watanabe S, Leja M, Line A, Eur J Histochem 2009 53 1 7 18 19351608
18. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H, Suzuki T, Cancer Sci 2012 103 1 136 143 10.1111/j.1349-7006.2011. 02119.x 21988594
19. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z, J Cancer Res Clin Oncol 2013 139 4 661 667 10.1007/s00432-012-1368-y 23292099
20. Cancer of the prostate. Bracarda S, De Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, De Braud F, Bartsch G, Crit Rev Oncol Hematol 2005 56 3 379 396 10.1016/j.critrevonc.2005.03.010 16310371 (Pubitemid 41677619)
21. The Zfx gene is expressed in human gliomas and is important in the proliferation and apoptosis of the human malignant glioma cell line U251. Zhou Y, Su Z, Huang Y, Sun T, Chen S, Wu T, Chen G, Xie X, Li B, Du Z, J Exp Clin Cancer Res 2011 30 114 10.1186/1756-9966-30-114 22185393
22. Anticancer activity of the iron facilitator LS081. Li Z, Tanaka H, Galiano F, Glass J, J Exp Clin Cancer Res 2011 30 34 10.1186/1756-9966-30-34 21453502
23. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? Carroll PR, J Urol 2005 173 4 1061 1062 10.1097/01.ju.0000156838.67623.10 15758699 (Pubitemid 40380501)
24. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. Yang L, You S, Kumar V, Zhang C, Cao Y, J Exp Clin Cancer Res 2012 31 40 10.1186/1756-9966-31- 40 22549243
25. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB, J Exp Clin Cancer Res 2013 32 9 10.1186/1756-9966-32-9 23406686
26. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R, J Exp Clin Cancer Res 2012 31 32 10.1186/1756-9966-31-32 22469146
27. PCA3 in the detection and management of early prostate cancer. Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W, Tumor Biol 2013 34 3 1337 1347 10.1007/s13277-013-0739-6
28. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Delgado PO, Alves BC, Gehrke Fde S, Kuniyoshi RK, Wroclavski ML, Del Giglio A, Fonseca FL, Tumor Biol 2013 34 2 983 986 10.1007/s13277-012- 0634-6
29. Clinical significance of NUCB2 mRNA expression in prostate cancer. Zhang H, Qi C, Li L, Luo F, Xu Y, J Exp Clin Cancer Res 2013 32 1 56 10.1186/1756-9966-32-56 23958433
30. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer. Zhang H, Qi C, Wang A, Li L, Xu Y, Tumor Biol 2013 DOI: 10.1007/s13277-013-1268-z
31. Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion? Diamandis EP, Clin Chem 2010 56 3 345 351 10.1373/clinchem.2009.140046 20093554
32. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH, J Transl Med 2011 9 153 10.1186/1479-5876-9-153 21917134
33. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW, Clin Cancer Res 2008 14 14 4400 4407 10.1158/1078-0432.CCR-07-4713 18628454